

Policy Number	RAD601.069
Policy Effective Date	12/01/2023
Policy End Date	12/31/2024

Myocardial Strain Imaging

Table of Contents
Coverage
Policy Guidelines
Description
Rationale
Coding
References
Policy History

Related Policies (if applicable)
None

Disclaimer

Carefully check state regulations and/or the member contract.
 Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. **If there is a discrepancy between a Medical Policy and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.**

Coverage

Myocardial strain imaging **is considered experimental, investigational and/or unproven** for all indications, including but not limited to use in individuals who have exposure to medications or radiation that could result in cardiotoxicity.

Policy Guidelines

None.

Description

Myocardial strain refers to the deformation (shortening, lengthening, or thickening) of the myocardium through the cardiac cycle. Myocardial strain can be measured by tissue Doppler imaging or, more recently, speckle-tracking echocardiography. Speckle-tracking echocardiography uses imaging software to assess the movement of specific markers in the myocardium that are detected in standard echocardiograms. It is proposed that a reduction in

myocardial strain may indicate sub-clinical impairment of the heart and can be used to inform treatment before development of symptoms and irreversible myocardial dysfunction.

Background

The term strain indicates dimensional or deformational change under force. When used in echocardiography, the term 'strain' is used to describe the magnitude of shortening, thickening and lengthening of the myocardium through the cardiac cycle. The most frequent measure of myocardial strain is the deformation of the left ventricle (LV) in the long axis, termed global longitudinal strain (GLS). During systole, ventricular myocardial fibers shorten with movement from the base to the apex. GLS is used as a measure of global LV function and provides a quantitative myocardial deformation analysis of each LV segment. Myocardial strain imaging is intended to detect subclinical changes in left ventricle function in patients with a preserved LV ejection fraction, allowing for early detection of systolic dysfunction. Since strain imaging can identify LV dysfunction earlier than standard methods, this raises the possibility of heart failure prophylaxis and primary prevention before the patient develops symptoms and irreversible myocardial dysfunction. Potential applications of speckle-tracking echocardiography are coronary artery disease, ischemic cardiomyopathy, valvular heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathies, stress cardiomyopathy, and chemotherapy-related cardiotoxicity.

Myocardial Strain Imaging

Myocardial strain can be measured by cardiac magnetic resonance imaging (MRI), tissue Doppler imaging, or by speckle-tracking echocardiography (STE). Tissue Doppler strain imaging has been in use since the 1990's but has limitations that include angle dependency and significant noise. In 2016, Smiseth et al. reported that the most widely used method of measuring myocardial strain at the present time is STE. (1) In STE, natural acoustic markers generated by the interaction between the ultrasound beam and myocardial fibers form interference patterns (speckles). These markers are stable, and STE analyzes the spatial displacement (tracking) of each point (speckle) on routine 2-dimensional sonograms. Echocardiograms are processed using specific acoustic-tracking software on dedicated workstations, with offline semiautomated analysis of myocardial strain. The 2-dimensional displacement is identified by a search with image processing algorithms for similar patterns across two frames. When tracked frame-to-frame, the spatiotemporal displacement of the speckles provides information about myocardial deformation across the cardiac cycle. GLS provides a quantitative analysis of each LV segment, which is expressed as a percentage. In addition to GLS, STE allows evaluation of LV rotational and torsional dynamics.

Regulatory Status

A number of image analysis systems have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. Examples of these are shown in Table 1. For example, the EchoInsight software system (Epsilon Imaging) "enables the production and visualization of 2-dimensional (2D) tissue motion measurements (including tissue velocities, strains, strain rates) and cardiac structural measurement information derived from tracking speckle in tissue regions visualized in any B mode (including harmonic) imagery loops as

captured by most commercial ultrasound systems" (K110447). The FDA determined that this device was substantially equivalent to existing devices (e.g., syngo U.S. Workplace, Siemens; K091286) for analysis of ultrasound imaging of the human heart.

Table 1. Examples of Software That Have Received FDA Clearance

Brand Name	Manufacturer	510(k) Number	FDA Product Code	Clearance Date
Myostrain	Myocardial Solutions	K182756	LNH	02/14/2019
Vivid	GE	K181685	IYN	10/25/2018
Aplio	Toshiba		IYN	01/11/2018
2D Cardiac Performance Analysis	Tomtec	K120135	LLZ	04/13/2012
EchoInsight	Epsilon Imaging	K110447	LLZ	05/27/2011
Q-lab	Phillips	K023877	LLZ	12/23/2002

FDA: Food and Drug Administration.

Rationale

This medical policy was created in January 2016 and has been updated regularly with a search of the PubMed database. The most recent literature search was conducted through March 14, 2022.

Medical policies assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Medical policies assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these policies, and credible information on technical reliability is available from other sources.

Myocardial Strain Imaging to Detect Cardiotoxicity

Clinical Context and Test Purpose

The purpose of myocardial strain imaging (MSI) in patients who have an indication for a transthoracic echocardiogram is to inform a decision whether to modify monitoring and/or treatment before the patient develops symptoms and irreversible myocardial dysfunction.

In 2019, the American College of Cardiology, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of

Nuclear Cardiology, Hearth Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons published appropriate use criteria for multimodality imaging in the assessment of cardiac structure and function in nonvalvular heart disease. (2) In 2019, the American College of Cardiology et al. considered strain imaging by speckle or tissue Doppler appropriate for the following indications:

- Initial evaluation prior to exposure to medications/radiation that could result in cardiotoxicity/heart failure;
- Re-evaluation (one year) in a patient previously or currently undergoing therapy with potentially cardiotoxic agents;
- Periodic re-evaluation in a patient undergoing therapy with cardiotoxic agents with worsening symptoms; and
- Evaluation of suspected hypertrophic cardiomyopathy.

The American College of Cardiology et al. recommended that MSI "may be appropriate" for indications that are described in Table 2. (See Table 2 under the Practice Guidelines and Position Statements section)

Cardiovascular complications of cancer treatment can be either acute or chronic (early or delayed) and include heart failure, myocardial ischemia or infarction, hypertension, thromboembolism, and arrhythmias. Presymptomatic detection of cardiotoxicity may allow modification of cancer therapy combinations or use of cardioprotective agents. Therefore, this medical policy will focus on clinical outcomes from use of strain imaging by speckle-tracking echocardiography or tissue Doppler imaging for the initial assessment and follow-up for cardiotoxicity.

The question addressed in this medical policy is: Does MSI improve the net health outcome in patients exposed to cardiotoxic agents?

The following PICO was used to select literature to inform this policy.

Populations

The relevant population of interest is individuals who have been exposed to cardiotoxic medications or radiation.

For patients who are undergoing chemotherapy, current recommendations are to measure ejection fraction (EF) prior to chemotherapy, at completion of therapy, and six months later. It has been proposed that the measurement of myocardial strain in addition to EF will be helpful in cases when EF is in the lower normal range, and in these cases, the finding of subnormal strain should result in closer monitoring of cardiac function, modification of cancer therapy, and/or use of cardioprotective agents.

Interventions

The test being considered is myocardial strain imaging. Strain is a dimensionless measure of tissue deformation $(L-L_0)/L_0$, where L is final length and L_0 the original length; positive values indicate lengthening, and negative values indicate shortening. (3)

The most frequent measure of myocardial strain imaging is global longitudinal strain, which averages values over the length of the myocardial wall. Positive values indicate lengthening, thickening, or clockwise rotation. Greater deformation is indicated by lower strain values. Cardiac strain in a healthy individual is generally around 20%, indicated in echocardiography by a negative number (-20). In a meta-analysis of 24 studies (2597 healthy volunteers), Yingchoncharoen et al. (2013), reported that global longitudinal strain varied from -15.9% to -22.1% (mean -19.7%, 95% confidence interval -18.9% to -20.4%). (4) Shortening of more than 20% is generally considered normal.

Comparators

The following tests are currently being used to make decisions about cardiac function: Tagged magnetic resonance imaging (MRI) is considered the reference standard for MSI. However, its routine use is limited by high cost, limited availability, complexity of acquisitions, and time-consuming image analysis. This medical policy will evaluate whether clinical outcomes are improved by myocardial strain imaging in comparison with EF.

Outcomes

The general outcomes of interest are symptoms and signs of cardiotoxicity. Cardiotoxicity is typically defined as a decline in EF but there is little consensus regarding what level of decline in left ventricle ejection fraction (LVEF) constitutes cardiotoxicity.

The beneficial outcome of a true-positive test result would be an increase in monitoring or modification of treatment that would reduce cardiotoxicity.

The beneficial outcome of a true-negative test result would be avoiding unnecessary treatment.

A harmful outcome of a false-positive test result would be unnecessary therapy.

A harmful outcome of a false-negative test result would be failure to diagnose cardiotoxicity or progression of toxicity.

Cardiotoxicity may be measured by clinical symptoms and EF at six months and after one, two and three years.

Study Selection Criteria

For the evaluation of clinical validity of MSI studies that meet the following eligibility criteria were considered:

- Reported on clinical outcomes;
- Included a suitable reference standard (EF);
- Patient/sample clinical characteristics were described;

- Patient/sample selection criteria were described.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Systematic Review

Thavendiranathan et al. (2014) conducted a systematic review of myocardial strain imaging for the early detection of cardiotoxicity in patients during and after cancer chemotherapy. (5) Searches were conducted through November 2013. The reviewers included prospective or retrospective studies of at least ten patients that used echocardiographic-based myocardial deformation parameters as the primary method to detect cardiotoxicity. Studies had to provide data on changes in deformation parameters and LVEF during therapy. The authors focused the review on three clinical scenarios: 1) detection of early myocardial changes; 2) prediction of subsequent cardiotoxicity; and 3) detection of late consequences of therapy (>1-year posttreatment).

Detection of early myocardial changes: Thirteen single-center cohort studies (n=384) provided information on MSI parameters to detect early myocardial changes in patients treated with anthracycline-containing regimens. The earlier studies (n=7) used tissue Doppler imaging while more recent studies (n=6) used STE. There was heterogeneity regarding patient age, types of cancer, strain techniques, and timing of follow-up but all the studies found that changes in myocardial deformation occurred earlier than changes in LVEF. In addition, reductions in myocardial deformation occurred at doses lower than those historically considered cardiotoxic.

Prognosis for early cardiotoxicity: Eight observational studies (n=452) included in the systematic review evaluated the prognostic value of MSI for subsequent cardiotoxicity (LVEF reduction or the development of heart failure). The studies differed in duration of follow-up (6 months, 12 to 15 months), treatment regimens, and other factors but used a similar definition of cardiotoxicity. The researchers found that an early fall in global longitudinal strain of 10% to 15% using STE predicted subsequent cardiotoxicity.

Prognosis for late cardiotoxicity: Nine case-control studies (n=436) were identified that compared findings in patients to controls. All of the studies used various myocardial deformation parameters to detect late subclinical cardiac injury, but none provided data on subsequent cardiac events.

The authors identified the following areas for future research:

- Determination of whether strain-based approaches could be reliably implemented in multiple centers, including nonacademic settings;
- Study in larger multicenter studies and in cancers other than breast cancer;
- Need to determine the optimum sampling (single or multiple);
- Comparison with a traditional LVEF-based approach;
- Understanding the long-term effect of strain changes that occur during therapy;

- The use of vendor-neutral methods to measure strain;
- The prognostic significance of strain abnormalities in survivors of cancer and those receiving radiation therapy;
- Whether intervention would change the natural course of the cardiac disease.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials.

In the multicenter, prospective, randomized, controlled, Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes (SUCCOUR) trial, anthracycline-treated patients with another heart failure risk factor (N=331) were randomly assigned to initiation of cardioprotective therapy guided by either a $\geq 12\%$ relative reduction in global longitudinal strain (n=166) or $>10\%$ absolute reduction in left ventricular ejection fraction (n=165). (6) Patients were enrolled at 28 centers from Australia, Asia, Europe, Canada, and the United States between January 2014 and December 2019. Cardioprotective therapy included initiation of an angiotensin converting enzyme (ACE) inhibitor (or an angiotensin receptor blocker [ARB], if the ACE inhibitor was not tolerated) followed by a beta-blocker, with doses titrated every 2 weeks until achievement of the maximal dose or development of intolerable side effects. The primary outcome was a difference in baseline to 1-year follow-up of left ventricular ejection fraction, preferentially based on 3D left ventricular ejection fraction, between the 2 groups. Twenty-four of the 331 randomized patients did not have a 1-year follow-up (2 died; 22 either withdrew consent or did not return for imaging); 307 patients were included in the final analysis (154 in the global longitudinal strain surveillance arm and 153 in the left ventricular ejection fraction surveillance arm). The majority of patients were female (94%) and had breast cancer (91%). Most patients were of European descent ($>60\%$ in each group), followed by East Asian (between 20% to 28% per group), South Asian (3.3% to 7.2%), and African (0.7% in each group).

The primary endpoint was not met as the difference of left ventricular ejection fraction between groups at 1-year follow-up was not statistically significant (global longitudinal strain: $57\% \pm 6\%$ vs. left ventricular ejection fraction: $55\% \pm 7\%$; $p=.05$). (6) Of patients in the left ventricular ejection fraction surveillance group, 13.7% met criteria for cancer-therapy-related cardiac dysfunction versus 5.8% in the global longitudinal strain group ($p=.02$). A subgroup analysis revealed that patients receiving cardioprotective medications in the left ventricular ejection fraction surveillance group had larger reductions in left ventricular ejection fraction at follow-up than in the global longitudinal strain surveillance group ($9.1\% \pm 10.9\%$ vs. $2.9\% \pm 7.4\%$; $p=.03$). More patients in the global longitudinal strain surveillance group received

cardioprotective treatment, which may account for this difference in ejection fraction. Limitations of the SUCCOUR trial include the potential for bias in local ejection fraction measurements since the sites were not blinded to study arm, the use of 2D left ventricular ejection fraction (instead of the preferential 3D) in some patients due to image quality, and a general shift toward use of non-anthracycline-based therapies in women with HER2+ breast cancer. With this shift, the focus on anthracycline-treated patients in the SUCCOUR trial may not be generalizable to those who are treated with non-anthracycline-based regimens. Of note, the adoption of global longitudinal strain-guided surveillance in routine practice also requires the commitment of echocardiography laboratories and training of analyzing/reporting clinicians. Additional studies are indicated to better define the threshold for cardioprotective therapy and to assess whether a global longitudinal strain-guided approach to cardioprotective therapy reduces the long-term risk of heart failure and improves clinical outcomes.

Section Summary: Myocardial Strain Imaging to Detect Cardiotoxicity

A systematic review of 13 studies with 384 patients treated for cancer suggests that MSI with tissue Doppler imaging or STE may be able to identify changes in myocardial deformation that precede changes in LVEF. Although MSI may detect sub-clinical myocardial changes, the value of these changes in predicting clinical outcomes or guiding therapy is uncertain. No studies were identified that compared MSI to LVEF. In the SUCCOUR trial, left ventricle surveillance with global longitudinal strain was associated with an increased use of cardioprotective therapy and a lower incidence of cancer-therapy-related cardiac dysfunction as compared to left ventricular ejection fraction surveillance. However, no difference in the primary endpoint of final left ventricular ejection fraction at 1-year follow-up was observed between the groups and interpretation of findings was limited by important design and relevance limitations.

Summary of Evidence

For individuals who have exposure to medications or radiation that could result in cardiotoxicity who receive myocardial strain imaging (MSI), the evidence includes a systematic review of observational studies and randomized controlled trials (RCT). Relevant outcomes include symptoms, morbid events, quality of life, treatment-related mortality, and treatment-related morbidity. A systematic review of 13 studies with 384 patients treated for cancer suggests that MSI with tissue Doppler imaging or speckle-tracking echocardiography (STE) may be able to identify changes in myocardial deformation that precede changes in left ventricular ejection fraction (LVEF). Although MSI may detect sub-clinical myocardial changes, the value of these changes in predicting clinical outcomes or guiding therapy is uncertain. In the SUCCOUR RCT, left ventricle surveillance with global longitudinal strain was associated with an increased use of cardioprotective therapy and a lower incidence of cancer-therapy-related cardiac dysfunction as compared to left ventricular ejection fraction surveillance. However, no difference in the primary endpoint of final left ventricular ejection fraction at 1-year follow-up was observed between the groups and interpretation of findings was limited by important design and relevance limitations. Additional studies are indicated to better define the threshold for cardioprotective therapy and assess whether a global longitudinal strain-guided approach to cardioprotective therapy reduces the long-term risk of heart failure and improves clinical

outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Practice Guidelines and Position Statements

American College of Cardiology (ACC) et al.

In 2019, the ACC, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons published appropriate use criteria for multimodality imaging in the assessment of cardiac structure and function in nonvalvular heart disease (see Table 2). (2)

Using a modified Delphi approach, the panel rated indications as “appropriate”, “may be appropriate”, and “not appropriate” (7) The specific studies that formed the basis of the ACC guidelines are not cited, however, they note that they used ACC/American Heart Association clinical practice guidelines whenever possible.

Of 81 indications considered for strain rate imaging, the panel rated only 4 as “appropriate” (Table 2). Three of the four concerned evaluation (initial or follow-up) in patients prior to and following exposure to potentially cardiotoxic agents. The other indication was follow-up testing to clarify initial diagnostic testing for patients with suspected hypertrophic cardiomyopathy. The guidelines did not separate out imaging with speckle tracking and tissue Doppler and did not make recommendations related to the comparative effectiveness of these imaging modalities.

The panel rated 14 other indications “may be appropriate” (Table 2). According to the panel, interventions in this category should be performed depending on individual clinical patient circumstances and patient and provider preferences, including shared decision making. (7)

Table 2. Summary of ACC Appropriate Use Criteria for Myocardial Strain Imaging

Clinical Scenario and Indication	Rating
<i>Initial evaluation in an asymptomatic patient:</i>	
Initial evaluation prior to exposure to medications/radiation that could result in cardiotoxicity/heart failure	Appropriate
Initial cardiac evaluation of a known systemic, congenital, or acquired disease that could be associated with structural heart disease	May be appropriate
Screening evaluation for structure and function in first-degree relatives of a patient with an inherited cardiomyopathy	May be appropriate
Pre-participation assessment of an asymptomatic athlete with 1 or more of the following: abnormal examination, abnormal ECG, or definite (or high suspicion for) family history of inheritable heart disease)	May be appropriate

Initial evaluation of a patient with clinical signs and/or symptoms of heart disease:	
Initial evaluation when symptoms or signs suggest heart disease	May be appropriate
Arrhythmias or conduction disorders <ul style="list-style-type: none"> Newly diagnosed left bundle branch block Nonsustained ventricular tachycardia 	May be appropriate
Palpitations/Presyncope/Syncope: Clinical symptoms or signs consistent with a cardiac diagnosis known to cause presyncope/syncope (including but not limited to hypertrophic cardiomyopathy and heart failure)	May be appropriate
Respiratory failure/exertional shortness of breath: Exertional shortness of breath/dyspnea or hypoxemia of uncertain etiology	May be appropriate
Heart failure/cardiomyopathy: <ul style="list-style-type: none"> Initial evaluation of known or suspected heart failure (systolic or diastolic) based on symptoms, signs, or abnormal test results to assess systolic or diastolic function and to assess for possible etiology (CAD, valvular disease) Suspected inherited or acquired cardiomyopathy (e.g., restrictive, infiltrative, dilated, hypertrophic) 	May be appropriate
Device therapy: Known implanted pacing/ICD/CRT device with symptoms possibly due to suboptimal device settings	May be appropriate
Cardiac transplantation: Monitoring for rejection or coronary arteriopathy in a cardiac transplant recipient	May be appropriate
Other: Suspected pericardial diseases	May be appropriate
Sequential or follow-up testing to clarify initial diagnostic testing:	
Evaluation of suspected hypertrophic cardiomyopathy	Appropriate
Re-evaluation (1 year) in a patient previously or currently undergoing therapy with potentially cardiotoxic agents	Appropriate
Periodic reevaluation in a patient undergoing therapy with cardiotoxic agents and worsening symptoms	Appropriate
Pulmonary hypertension in the absence of severe valvular disease	May be appropriate
Comprehensive further evaluation of undefined cardiomyopathy	May be appropriate
Evaluation of suspected cardiac amyloidosis	May be appropriate
Sequential or follow-up testing: New or Worsening Symptoms or to Guide Therapy	
Re-evaluation of known structural heart disease with change in clinical status or cardiac examination or to guide therapy	May be appropriate
Re-evaluation of known cardiomyopathy with a change in clinical status or cardiac examination or to guide therapy	May be appropriate
Re-evaluation of known HF (systolic or diastolic) with a change in clinical status or cardiac examination without a clear precipitating change in medication or diet	May be appropriate
Re-evaluation for CRT device optimization in a patient with worsening HF	May be appropriate

ACC: American College of Cardiology; CAD: coronary artery disease; CRT: cardiac resynchronization therapy; ECG: electrocardiogram; HF: heart failure; ICD: implantable cardioverter-defibrillator; LBBB: left bundle branch block; VT: ventricular tachycardia.

Source: Adapted from Doherty et al. (2019). (2)

American Society of Clinical Oncology

In 2017, the American Society of Clinical Oncology noted that measurement of strain has been demonstrated to have some diagnostic and prognostic use in patients with cancer receiving cardiotoxic therapies but that there have been no studies demonstrating that early intervention based on changes in strain alone can result in changes in risk and improved outcomes. (8) The American Society of Clinical Oncology also notes that screening for asymptomatic cardiac dysfunction using advanced imaging could lead to added distress in cancer survivors.

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this policy are listed in Table 3.

Table 3. Summary of Key Trials

Study	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT04547465	2D Speckle-training Echocardiography in Chemotherapy-induced Cardiomyopathy with Cardiovascular Risk Factors	300	Jun 2023
NCT04429633	Strain-based vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention Strategy in Patients with Breast Cancer Who Treated with Adjuvant Trastuzumab	136	Jul 2023
Unpublished			
NCT03543228 ^a	MyoStrain CMR for the Detection of Cardiotoxicity (Prefect)	50	Jun 2019
NCT02605512	Early Detection and Prediction of Cardiotoxicity in Radiotherapy-treated Breast Cancer Patients (BACCARAT)	120	Sep 2020 (unknown)
NCT02286908	Global Strain and Mechanical Dispersion May Predict Death and Ventricular Arrhythmias Better Than Ejection Fraction	3100	Dec 2021 (recruiting)
NCT03297346	Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer (EARLY-HEART)	250	May 2021 (unknown)

NCT: national clinical trial.

^a Denotes industry-sponsored or cosponsored trial.

Coding

Procedure codes on Medical Policy documents are included **only** as a general reference tool for each policy. **They may not be all-inclusive.**

The presence or absence of procedure, service, supply, or device codes in a Medical Policy document has no relevance for determination of benefit coverage for members or reimbursement for providers. **Only the written coverage position in a Medical Policy should be used for such determinations.**

Benefit coverage determinations based on written Medical Policy coverage positions must include review of the member's benefit contract or Summary Plan Description (SPD) for defined coverage vs. non-coverage, benefit exclusions, and benefit limitations such as dollar or duration caps.

CPT Codes	93356
HCPCS Codes	C9762, C9763

*Current Procedural Terminology (CPT®) ©2022 American Medical Association: Chicago, IL.

References

1. Smiseth O, Torp H, Opdahl A, et al. Myocardial strain imaging: how useful is it in clinical decision making? *Eur Heart J*. Oct 2015; 37(15):1196-1207. PMID 26508168
2. Doherty J, Kort S, Mehran R, et al. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/ SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons. *J Am Soc Echocardiogr*, May 2019; 32(5):553-579. PMID 30744922
3. Trivedi SJ, Altman M, Stanton T, et al. Echocardiographic Strain in Clinical Practice. *Heart Lung Circ*. Sep 2019; 28(9):1320-1330. PMID 31064715
4. Yingchoncharoen T, Agarwal S, Popovic Z, et al. Normal ranges of left ventricular strain: a meta-analysis. *J Am Soc Echocardiogr*, Feb 2013; 26(2):185-191. PMID 23218891
5. Thavendiranathan P, Poulin F, Lim K, et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. *J Am Coll Cardiol*. Jul 2014; 63(25 Pt A):2751-2768. PMID 24703918
6. Thavendiranathan P, Negishi T, Somerset E, et al. Strain-guided management of potentially cardiotoxic cancer therapy. *J Am Coll Cardiol*. Feb 2 2021; 77(4):392-401. PMID 33220426
7. Hendel R, Lindsay B, Allen J, et al. ACC Appropriate Use Criteria Methodology: 2018 Update: A Report of the American College of Cardiology Appropriate Use Criteria Task Force. *J Am Coll Cardiol*. Feb 2018; 71(8):935-948. PMID 29471942
8. Armenian S, Lacchetti C, Lenihan D. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. *J Oncol Pract*. Apr 2017; 13(4):270-275. PMID 27922796

Centers for Medicare and Medicaid Services (CMS)

The information contained in this section is for informational purposes only. HCSC makes no representation as to the accuracy of this information. It is not to be used for claims adjudication for HCSC Plans.

The Centers for Medicare and Medicaid Services (CMS) does not have a national Medicare coverage position. Coverage may be subject to local carrier discretion.

A national coverage position for Medicare may have been developed since this medical policy document was written. See Medicare's National Coverage at <<http://www.cms.hhs.gov>>.

Policy History/Revision	
Date	Description of Change
12/01/2023	Reviewed. No changes.
10/01/2022	Document updated with literature review. Coverage unchanged. Reference 6 added; one reference removed.
09/15/2021	Document updated with literature review. Coverage statement clarified to state: Myocardial strain imaging is considered experimental, investigational and/or unproven for all indications, including but not limited to use in individuals who have exposure to medications or radiation that could result in cardiotoxicity. No references added.
11/15/2020	Document updated with literature review. Coverage unchanged. Reference 3 added.
11/15/2019	Document updated with literature review. Coverage unchanged. All other policy sections were significantly revised, including the reference section in which all references were newly added. Document title changed from: Myocardial Deformation Imaging (Strain Imaging).
10/15/2018	Reviewed. No changes.
12/15/2017	Document updated with literature review. Coverage unchanged.
12/01/2016	Reviewed. No changes.
01/01/2016	New medical document. Myocardial deformation imaging (strain imaging) is considered experimental, investigational and/or unproven.